Literature DB >> 26893711

Downregulation of miR-362-5p inhibits proliferation, migration and invasion of human breast cancer MCF7 cells.

Fang Ni1, Zhaohua Gui1, Qiang Guo1, Zhongqian Hu1, Xinyi Wang1, Danlei Chen1, Siying Wang1.   

Abstract

An increasing number of studies have indicated that the deregulation of microRNAs (miRNAs) contributes to tumorigenesis and metastasis. In the present study, significant upregulation of miR-362-5p was identified in the breast cancer MDA-MB-231 and MCF7 cell lines compared with the control CCD-1095Sk cell line. The inhibition of miR-362-5p was demonstrated to significantly inhibit the cell proliferation, migration and invasion of human breast cancer MCF7 cells. In addition, the knockdown of miR-362-5p induced G1 arrest and promoted apoptosis in the breast cancer cells. Mechanistic investigations confirmed that the tumor suppressor gene CYLD is a direct target of miR-362-5p. The ectopic expression of miR-362-5p represses CYLD expression, whereas miR-362-5p inhibitor treatment induces CYLD protein expression and decreases NF-κB expression in the downstream signaling pathway. Thus, these findings may provide novel insights into the molecular mechanisms through which miR-362-5p regulates breast cancer cell proliferation, migration and invasion. This study also suggests that miR-362-5p may act as a novel potential therapeutic target for the treatment of breast cancer.

Entities:  

Keywords:  breast cancer; invasion; miR-362-5p; migration; proliferation

Year:  2015        PMID: 26893711      PMCID: PMC4734047          DOI: 10.3892/ol.2015.3993

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Identification of the familial cylindromatosis tumour-suppressor gene.

Authors:  G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells.

Authors:  L L Deng; Y X Shao; H F Lv; H B Deng; F Z Lv
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

Review 3.  Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells.

Authors:  Marina Chekulaeva; Witold Filipowicz
Journal:  Curr Opin Cell Biol       Date:  2009-05-18       Impact factor: 8.382

Review 4.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

5.  Clinical significance of CYLD downregulation in breast cancer.

Authors:  Mitsuhiro Hayashi; Hirofumi Jono; Satoru Shinriki; Takuya Nakamura; Jianying Guo; Aiko Sueta; Mai Tomiguchi; Saori Fujiwara; Mutsuko Yamamoto-Ibusuki; Kei-Ichi Murakami; Satoshi Yamashita; Yutaka Yamamoto; Jian-Dong Li; Hirotaka Iwase; Yukio Ando
Journal:  Breast Cancer Res Treat       Date:  2014-01-08       Impact factor: 4.872

6.  Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.

Authors:  Toni Urbanik; Bruno Christian Köhler; Regina Johanna Boger; Marcus Alexander Wörns; Steffen Heeger; Gerd Otto; Nadine Hövelmeyer; Peter Robert Galle; Marcus Schuchmann; Ari Waisman; Henning Schulze-Bergkamen
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

7.  CYLD and HCC: when being too sensitive to your dirty neighbors results in self-destruction.

Authors:  Joan Font-Burgada; Ekihiro Seki; Michael Karin
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

8.  The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.

Authors:  Andrew Kovalenko; Christine Chable-Bessia; Giuseppina Cantarella; Alain Israël; David Wallach; Gilles Courtois
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

Review 9.  MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?

Authors:  Silvia Giordano; Amedeo Columbano
Journal:  Hepatology       Date:  2012-12-26       Impact factor: 17.425

10.  A novel player in inflammation and cancer: the deubiquitinase CYLD controls HCC development.

Authors:  Jeremie Gautheron; Tom Luedde
Journal:  J Hepatol       Date:  2012-08-07       Impact factor: 25.083

View more
  11 in total

1.  MicroRNA-154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells.

Authors:  Chengwei Qin; Yanming Zhao; Chunzhi Gong; Zhenlin Yang
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

Review 2.  Tumor-derived exosomes, microRNAs, and cancer immune suppression.

Authors:  Michael W Graner; Sathya Schnell; Michael R Olin
Journal:  Semin Immunopathol       Date:  2018-06-04       Impact factor: 9.623

3.  MicroRNA expression profiling of porcine mammary epithelial cells after challenge with Escherichia coli in vitro.

Authors:  A Jaeger; F Hadlich; N Kemper; A Lübke-Becker; E Muráni; K Wimmers; S Ponsuksili
Journal:  BMC Genomics       Date:  2017-08-24       Impact factor: 3.969

4.  Blood and lung microRNAs as biomarkers of pulmonary tumorigenesis in cigarette smoke-exposed mice.

Authors:  Alberto Izzotti; Roumen Balansky; Gancho Ganchev; Marietta Iltcheva; Mariagrazia Longobardi; Alessandra Pulliero; Marta Geretto; Rosanna T Micale; Sebastiano La Maestra; Mark Steven Miller; Vernon E Steele; Silvio De Flora
Journal:  Oncotarget       Date:  2016-12-20

5.  MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma.

Authors:  Dan Wang; Hongyan Wang; Yichun Li; Qian Li
Journal:  Biosci Rep       Date:  2018-06-21       Impact factor: 3.840

6.  The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.

Authors:  Athanasios Pseftogas; Konstantinos Xanthopoulos; Theofilos Poutahidis; Chrysanthi Ainali; Dimitra Dafou; Emmanuel Panteris; Joseph G Kern; Xaralabos Varelas; Alexander Hardas; Christos Gonidas; Anastasia Tsingotjidou; Eudoxia Hatzivassiliou; George Mosialos
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

7.  Increased Formation of Follicular Antrum in Aquaporin-8-Deficient Mice Is Due to Defective Proliferation and Migration, and Not Steroidogenesis of Granulosa Cells.

Authors:  Dejiang Wang; Xiangjun Di; Jie Wang; Miao Li; Di Zhang; Yaxin Hou; Jiao Hu; Ge Zhang; He Zhang; Meiyan Sun; Xiangyu Meng; Bo Sun; Chunlai Jiang; Tonghui Ma; Weiheng Su
Journal:  Front Physiol       Date:  2018-08-23       Impact factor: 4.566

8.  MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.

Authors:  Xiaoli Wei; Mengru Gao; Yaser Ahmed; Min Gao; Wenbo Liu; Yiyin Zhang; Xiaoque Xie; Qihong Zhao; Hua Wang; Kangsheng Gu
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

9.  Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.

Authors:  Xiaoqing Zhang; Qi He; Leiqin Sun; Yanfei Zhang; Shengying Qin; Junwei Fan; Jianfeng Wang
Journal:  Dis Markers       Date:  2019-12-16       Impact factor: 3.434

10.  MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI.

Authors:  Xiaosong Wei; Beibei Wang; Qi Wang; Xiaoming Yang; Yang Yang; Zhiwei Fang; Chengzhi Yi; Lei Shi; Xin Fan; Jin Tao; Yufeng Guo; Dongkui Song
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.